Abstract
Chemotherapeutic options for androgen-independent prostate cancer are extremely limited with minimum survival advantage. The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against the human prostate cancer androgen-independent cell, PC-3, which demonstrated an IC50 value of 56 x 10-6 mol/L compared to 5.6 x 10-6 mol/L for cisplatin. Then Titanocene Y was given at the maximum tolerable dose of 40 mg/kg/d on five consecutive days to one cohort of eight PC3 tumor-bearing male NMRI:nu/nu mice, while a second cohort was treated similarly with 3 mg/kg/d of cisplatin. Both of these mouse cohorts showed a statistically significant tumor growth reduction with respect to the third solvent-treated control group, which led to T/C values of 42% for cisplatin and 52% for Titanocene Y at the end of the experiment. This encouraging activity of Titanocene Y against prostate tumors in vivo, which is almost comparable with respect to cisplatin hopefully leads to further development of Titanocene Y in the future.
Keywords: Anti-cancer drug, Cisplatin, Titanocene, Prostate Cancer, PC-3, Xenograft
Letters in Drug Design & Discovery
Title: Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice
Volume: 5 Issue: 2
Author(s): Catherine M. Dowling, James Claffey, Sandra Cuffe, Iduna Fichtner, Clara Pampillon, Nigel J. Sweeney, Katja Strohfeldt, R. William G. Watson and Matthias Tacke
Affiliation:
Keywords: Anti-cancer drug, Cisplatin, Titanocene, Prostate Cancer, PC-3, Xenograft
Abstract: Chemotherapeutic options for androgen-independent prostate cancer are extremely limited with minimum survival advantage. The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against the human prostate cancer androgen-independent cell, PC-3, which demonstrated an IC50 value of 56 x 10-6 mol/L compared to 5.6 x 10-6 mol/L for cisplatin. Then Titanocene Y was given at the maximum tolerable dose of 40 mg/kg/d on five consecutive days to one cohort of eight PC3 tumor-bearing male NMRI:nu/nu mice, while a second cohort was treated similarly with 3 mg/kg/d of cisplatin. Both of these mouse cohorts showed a statistically significant tumor growth reduction with respect to the third solvent-treated control group, which led to T/C values of 42% for cisplatin and 52% for Titanocene Y at the end of the experiment. This encouraging activity of Titanocene Y against prostate tumors in vivo, which is almost comparable with respect to cisplatin hopefully leads to further development of Titanocene Y in the future.
Export Options
About this article
Cite this article as:
Dowling M. Catherine, Claffey James, Cuffe Sandra, Fichtner Iduna, Pampillon Clara, Sweeney J. Nigel, Strohfeldt Katja, G. Watson William R. and Tacke Matthias, Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice, Letters in Drug Design & Discovery 2008; 5 (2) . https://dx.doi.org/10.2174/157018008783928463
DOI https://dx.doi.org/10.2174/157018008783928463 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>In vitro and In vivo</i> Effects of 17β-N-(4-phenylcarbamoyl) androst-4-en-3- one Derivatives as 5a-reductase Inhibitors on Androgen-dependent Glands
Current Enzyme Inhibition G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Magnetomotive Molecular Nanoprobes
Current Medicinal Chemistry Resisting the Resistance in Cancer: Cheminformatics Studies on Short- Path Base Excision Repair Pathway Antagonists Using Supervised Learning Approaches
Combinatorial Chemistry & High Throughput Screening Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment
Anti-Cancer Agents in Medicinal Chemistry Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications
Current Signal Transduction Therapy Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Effects of Galbanic Acid on Proliferation, Migration, and Apoptosis of Glioblastoma Cells Through the PI3K/Akt/MTOR Signaling Pathway
Current Molecular Pharmacology Extracellular Citrate in Health and Disease
Current Molecular Medicine